Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.
Satoru MiuraHyun Ae JungShin Yup LeeSeung-Hyeun LeeMin Ki LeeYong Chul LeeMaximilian J HochmairCheng-Ta YangAngela MärtenJames Chih-Hsin YangSanjay PopatPublished in: OncoTargets and therapy (2022)
mutation-positive NSCLC and T790M-mediated acquired resistance, especially those with Del19-positive disease. Activity was observed across "real-world" patients including those with poor ECOG PS and/or brain metastases. ECOG PS and incidence of brain metastases remained stable prior to, and after, afatinib.
Keyphrases
- brain metastases
- small cell lung cancer
- disease activity
- epidermal growth factor receptor
- systemic lupus erythematosus
- rheumatoid arthritis
- end stage renal disease
- advanced non small cell lung cancer
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- chronic kidney disease
- ankylosing spondylitis
- prognostic factors
- peritoneal dialysis
- juvenile idiopathic arthritis
- risk factors
- patient reported outcomes
- tyrosine kinase
- patient reported